We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

Back to rankings

142 hedge funds and large institutions have $422M invested in Sciclone Pharmaceuticals Inc in 2017 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 56 increasing their positions, 39 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 39

33% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 18

15% more capital invested

Capital invested by funds: $366M → $422M (+$55.6M)

4% more funds holding

Funds holding: 136 → 142 (+6)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

82% less call options, than puts

Call options by funds: $214K | Put options by funds: $1.17M

Holders
142
Holders Change
+6
Holders Change %
+4.41%
% of All Funds
3.54%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
24
Increased
56
Reduced
39
Closed
18
Calls
$214K
Puts
$1.17M
Net Calls
-$959K
Net Calls Change
-$983K

Top Buyers

Rank Fund Capital Flow
1
GP
GLG Partners
United Kingdom
+$12.3M
2
Two Sigma Investments
Two Sigma Investments
New York
+$6.99M
3
Renaissance Technologies
Renaissance Technologies
New York
+$4.56M
4
OAM
Oxford Asset Management
United Kingdom
+$4M
5
GH
GAM Holding
Switzerland
+$3.87M

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$18.5M
2
SCM
Stonepine Capital Management
Oregon
-$14.5M
3
PRCM
Pine River Capital Management
Minnesota
-$3.98M
4
BlackRock
BlackRock
New York
-$2.45M
5
SFM
Systematic Financial Management
New Jersey
-$1.32M
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
101
Cubist Systematic Strategies
Connecticut
$195K +$177K +17,707 New
JMPWA
102
JP Morgan Private Wealth Advisors
California
$192K – – –
TSS
103
Two Sigma Securities
New York
$191K +$174K +17,407 New
DAM
104
DLD Asset Management
New York
$190K +$173K +17,300 New
BNP Paribas Financial Markets
105
BNP Paribas Financial Markets
France
$178K +$56.6K +5,658 +54%
Los Angeles Capital Management
106
Los Angeles Capital Management
California
$167K -$16K -1,600 -10%
KAM
107
Kassirer Asset Management
Ontario, Canada
$165K +$150K +15,000 New
NCCM
108
Nine Chapters Capital Management
New Jersey
$150K -$271K -27,100 -67%
Susquehanna International Group
109
Susquehanna International Group
Pennsylvania
$142K +$129K +12,901 New
MSA
110
Mason Street Advisors
Wisconsin
$140K +$7.2K +720 +6%
O
111
OppenheimerFunds
New York
$135K -$9.74K -974 -7%
TI
112
Telemetry Investments
New York
$132K +$120K +12,000 New
UBS AM
113
UBS AM
Illinois
$124K – – –
PIA
114
Piedmont Investment Advisors
North Carolina
$123K +$112K +11,185 New
PA
115
Profund Advisors
Maryland
$113K +$103K +10,294 New
LIA
116
LS Investment Advisors
Michigan
$112K -$1.17K -117 -1%
SOADOR
117
State of Alaska Department of Revenue
Alaska
$112K +$45K +4,503 +79%
Fidelity Investments
118
Fidelity Investments
Massachusetts
$110K – – –
NA
119
NewEdge Advisors
Louisiana
$109K – – –
FPF
120
FNY Partners Fund
New York
$88K +$80K +8,000 New
PA
121
Parallel Advisors
California
$77K – – –
AIM
122
Acrospire Investment Management
Illinois
$77K +$13.2K +1,320 +23%
PI
123
PineBridge Investments
New York
$75K +$1.01K +101 +2%
PCM
124
Prelude Capital Management
New York
$67K -$186K -18,551 -75%
AIP
125
Ameritas Investment Partners
Nebraska
$50K +$7.3K +730 +19%
3 4
5
6 7

SCLN Hedge Fund Activity: Q2 2017 in Review

142 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q2 2017, worth a combined $422M — up 15% from $366M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new SCLN positions and 18 closed out — a net gain of 6 holders — while 56 added to existing stakes and 39 trimmed.

The largest buyer was GLG Partners, adding an estimated $12.3M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $18.5M sold.

  • 142 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q2 2017, up from 136 in Q1 2017.
  • Funds reported $422M of Sciclone Pharmaceuticals Inc stock for Q2 2017, up 15% quarter-over-quarter.
  • 24 funds opened new Sciclone Pharmaceuticals Inc positions in Q2 2017 and 18 closed out, a net change of +6 holders.
  • The largest Sciclone Pharmaceuticals Inc buyer in Q2 2017 was GLG Partners, an estimated $12.3M added.
  • The largest Sciclone Pharmaceuticals Inc seller in Q2 2017 was Nantahala Capital Management, an estimated $18.5M sold.

Based on aggregated 13F filings for Q2 2017.